T cells recognize antigenic peptides displayed on the surface of MHC-bearing antigen-presenting cells (APCs), and with sufficient costimulation become activated. However, the ability of an APC (even bearing the correct peptide) to initiate and fulfill the requirements for T cell activation is not easily achieved. Naive T cells use multiple copies of a single receptor to survey the vast array of peptides presented on an APC, and require multiple receptor engagements to initiate T cell activation. Dendritic cells (DCs) are specialized cells with optimal capabilities for priming naive CD4+ T cells. Activation occurs, after initial antigen recognition by T cells, followed by a rapid dialogue between the T cells and the DCs. The resulting changes in both the cytoskeleton and the expression or regulation of cell-surface molecules on both cell types act to further strengthen engagement. In this report, we review the fundamentals of CD4+ T helper cell : DC interactions and discuss recent data concerning the molecular characteristics of this engagement.
INTRODUCTION
The ability of the immune system to identify and eliminate infectious agents is orchestrated by a continuous network of highly specialized and varied species of cells, each with a unique relationship to one another. One such specialized cell is the dendritic cell (DC) present in all tissues except the brain. DCs serve as sentinels for the immune system, particularly in the skin, mucosal sites, and the lungs, and are among the earliest cell populations to come into direct contact with invading organisms. DC progenitors, originating from bone marrow, enter the blood and seed nonlymphoid tissues where they exist in an immature phenotype with optimal capabilities for antigen-uptake, processing, and the formation of foreign-peptide complexes (reviewed in Banchereau et al 1 ) . The ability of DCs to reside in such tissues where they take up and process foreign antigens before migrating to secondary lymphoid organs is an essential function of their antigen-presenting role.
Once triggered by antigen and 'danger signals', immature DCs in peripheral tissues mature and carry antigen via the lymphatic system into the T cell regions of draining lymph nodes where they stimulate primary and memory T cell responses. Cytokines such as SLC and MIP-3b direct maturing peptide-laden DCs from inflamed tissues into the lymphatics towards the draining lymph node and subsequently to the para-cortical area of the lymph node, to ensure an encounter with naive T cells. [2] [3] [4] Following activation in the lymph node, effector T cells migrate through blood and lymph, attach to 'activated' blood vessels, transmigrate, and home to the site(s) of infection/inflammation. [3] [4] [5] Besides their role in activation of naive cells, DCs are central players in the development of antibody responses because of the requirement for activated CD4+ helper T cells in the differentiation of B cells into antibody-secreting plasma cells. 6, 7 B cells must encounter activated T cells that recognize the peptide antigens displayed by the B cells that the naive T cells initially recognized in the lymphoid tissue on the surface of DCs. Via their activation of CD4+ helper T cells and CD8+ cytotoxic T cells (CTLs), and the subsequent interaction of helper T cells with B cells, DCs dictate both the nature and potency of the immune response. In addition, differential molecular interactions between DCs and naive T cells are important mediators of T cell tolerance both in central tolerance to self-antigens and in the generation and maintenance of peripheral tolerance. In the following review, we wish to focus primarily on the molecular interactions that occur between DCs and CD4+ T cells both in an antigen-independent and antigen-dependent setting. The relevance of the interactions described herein will be in the context of the priming of naive T cells required in the immune response to foreign antigens.
CHOOSING POTENTIAL PARTNERS: ANTIGEN-INDEPENDENT INTERACTIONS
Naive T cells bearing T cell receptors (TCRs) specific for a particular antigen are rare (r1 in 50-100 Â 10
3 ) and therefore an antigen-independent mechanism must be in place to promote efficient sampling by T cells of peptide-bearing antingen-presenting cells (APCs). 8, 9 The most commonly used term to describe this process is 'clustering' or aggregate formation, which occurs after multiple transient interactions of T cells with antigen-loaded APCs. [8] [9] [10] [11] These interactions are facilitated mainly by integrins and several members of the immunoglobulin superfamily (IgSF). 12, 13 In the event of recognition by the TCR of the correct peptide in the context of self-MHC Class II, the DC-T cell interaction is further stabilized by increased expression of the appropriate adhesion molecules. Intercellular adhesion molecule-1 (ICAM-1) expression, present at low levels on immature DC, is rapidly increased as a result of retrograde signaling via the T lymphocyte. Accordingly, monoclonal antibodies (mAbs) against both ICAM-1 and its T cell ligand LFA-1 strongly inhibit aggregate formation and the resultant signaling between T cells and blood DCs.
14 However, it is ICAM-3, constitutively expressed at high densities on DCs, that promotes the initial cluster formation. It is likely that ICAM-1 upregulation and adhesion is important in stabilizing antigen-dependent interactions. ICAM-2 is also present, but contributes little during the initial interaction. 13, 15 Recently, a novel DC-specific molecule known as DC-SIGN (DC-specific ICAM-3-grabbing nonintegrin) has been suggested to be the main adhesion receptor involved in initial adhesive contacts with naive T cells, as opposed to LFA-1.
16,17 DC-SIGN (CD209) is a Type II transmembrane protein belonging to the C-type lectin family and has very high affinity for ICAM-2 and ICAM-3. The initial clustering of DC-SIGN with ICAM-3 on resting T cells facilitates the formation of multiple low-avidity LFA-1-ICAM-1 binding partner engagements and thus allows the TCR to sample MHC-peptide complexes within the contact area. 17, 18 DC-SIGN has also been shown to be involved in DC migration, Ag-uptake, and presentation, and even as a receptor for HIV (as reviewed in Geijtenbeek et al 16 ). However, it should be noted that DC-SIGN is restricted to immature DCs in peripheral tissues and mature DCs in lymphoid organs, but is not expressed on follicular DCs (FDC) or CD1a+ Langerhans cells of the epidermis. Neither FDCs nor epidermal Langerhans cells present antigen. However, upon maturation that may occur with in vitro culture or upon antigen capture in vivo, DC-SIGN expression is induced on Langerhans cells.
DCs have several advantages over other APCs (B lymphocytes and macrophages) in the activation of T cells, one such advantage being their ability to form antigen-independent interactions with T cells. 19 B lymphocytes require antigen in order to make adhesive contacts with interacting T cells. Additionally, even in the absence of antigen, DCs have been shown to induce small Ca 2+ influxes during these initial interactions leading to a limited but measurable burst of T cell proliferation. 19, 20 It has been suggested that antigenindependent interactions may deliver a survival signal to the T lymphocyte. 7, 19, 21 Indeed, in mice lacking MHC molecules 21, 22 or TCR expression, 23 it has been demonstrated that they have low numbers of lymphocytes. This aspect of T cell survival is still controversial, but it would seem unreasonable to envision that the T cell repertoire declines without presentation and recognition of an 'appropriate' peptide within a certain time frame. A simple survival signal, perhaps induced by antigen-independent 'tickling' of naive T cells by DCs, could account for the ability of a diverse pool of TCRs necessary for protective immunity to be maintained in the absence of engagement with their cognate antigen. Indeed, it has been shown in vitro that interactions of murine DCs with syngeneic polyclonal naive T cells in the absence of antigen lead to several T cell responses including small Ca 2+ fluxes, low levels of proliferation, and long-term survival. 24 This was also found in experiments using MHC-deficient DCs, indicating the significance of adhesive interactions between these cells in maintenance of the naive T cell repertoire in vivo.
Alternatively, given the current view of thymic selection, it is plausible that T cells engage frequently with their 'selfselecting' ligand in the periphery, without full activation, but with sufficient engagement to allow 'survival'. Following their initial encounter with antigen on DCs, CD4+ T cells that do not recognize the specific peptide complementary to it's TCR with sufficient avidity simply break loose from the tether and continue to circulate through blood and lymph. 1 However, those naive T cells that recognize the appropriate peptide-MHC complex increase adhesive contacts with DCs and recruit essential machinery required for activation at the site of membrane contact.
MAKING DECISIONS: ANTIGEN-DEPENDENT INTERACTIONS Molecular events involved in T cell signaling are relatively complex, requiring the engagement of several extracellular molecules and translating these signals into intracellular events to control T cell activation, proliferation, survival, apoptosis, and/or nonresponsiveness. 25 Recognition of the correct MHC-peptide complex by naive CD4+ T cells via its antigen-specific TCR constitutes signal 1 and may provide a permissive signal to the T cell to prepare for full activation. According to the two-signal theory, TCR occupancy alone is not sufficient to permit T cell activation and may result in the induction of T cell nonresponsiveness or anergy. [26] [27] [28] Accessory molecule interactions are necessary to sustain T cell activation and provide one or more costimulatory events, signal 2, and these include specific interactions between co-stimulatory molecules on the T cells and their specific ligand(s) on DCs (Table 1) . 29 The presence of these ligands on APCs and not on other tissues (excluding inflamed tissue) ensures that the ability to activate T cells is restricted to those cells that can present antigen under costimulatory conditions and lead to full T cell activation.
COSTIMULATION: CONTROLLING T CELL FATE
It is widely accepted that CD28, present on most T cells, is the primary or 'classical' costimulatory molecule that is required for delivering signal 2. 30, 31 This has been demonstrated in numerous experimental settings using mAbs or the natural ligands CD80 (B7.1) and CD86 (B7.2).
32-34 Both CD80 and CD86 expression are increased on the surface of DCs following DC activation. 33, 34 The triggering of CD3 and CD28 with specific mAbs is commonly used by many investigators and is considered the 'gold standard' for the induction of T cell activation. However, CD28-deficient mice are still able to mount T cell responses, although very limited, as a result of CD2 interactions with its ligand LFA-3 present on the APC cell surface. 35 It is appreciated that these mice can initiate responses to antigen in the absence of CD28, but they are not able to sustain proliferative T cell responses. 35, 36 Double-deficient mice (CD28 À /CD2 À ) exhibit a complete loss of mitogenic and antigen-specific T cell responses. 37 These results indicate a costimulatory function for CD2, which belongs to the same immunoglobulin superfamily as CD28. CD2 and CD28 may function in concert with one another to stabilize the formation of membrane contacts between the T cell and the APC (Table 1) . However, the dominance of CD28-mediated costimulation in the initiation and maintenance of T cell proliferative responses has been demonstrated reproducibly in vitro and in vivo. Blockade of CD28, in vivo, reduces systemic immune responses as demonstrated in experimental animal models to prevent graft rejection as well as autoimmune diseases. 30, 31 In recent years, a number of other molecules in the CD28 family have emerged and share common structural and functional elements with CD28. 31 These include, in addition to CD28, inducible costimulator (ICOS), cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and several novel homologues. Despite their homology to CD28, both CTLA-4 and PD-1 function as negative regulators of T cell activation. All belong to IgSF and possess a single Ig-V-like extracellular domain necessary for binding to their ligands. ICOS maps to the same genetic region as CD28 and has costimulatory properties. 31 Investigators of T cell biology have also provided us with additional candidates that have shown costimulatory properties such as OX40, a member of the TNF/nerve growth factor receptor family. 38 Accordingly, its expression is restricted to activated CD4+ and CD8+ lymphocytes, and its binding partner OX-40 ligand (OX40L) is found on DCs, CD40L-activated B lymphocytes, and even on EBV-transformed B cells. 39, 40 4-IBB is a T cell antigen and another member of the TNF/nerve growth factor receptor family and induced during early activation of T cells. It also appears to have costimulatory properties. 41 Its ligand 4IBB-L is expressed on mature DCs and complements the function of OX40L. 13, 42, 43 Another candidate is signaling lymphocyte activation molecule (SLAM) or CD150 that belongs to a subfamily of the immunoglobulin superfamily including 2B4, Ly-9, and CD84. 44 It is found on the surface of, and increased with activation on, T, B, and DCs. 45, 46 Engagement of SLAM with specific mAbs has been demonstrated to promote T cell proliferation in a CD28-and IL-2-independent manner. 45, 46 47 CTLA-4 is absent from the surface of most resting T cells but appears on the surface several hours following T cell activation. It should be noted that polarization and rapid surface expression of CTLA-4 has yet to be shown upon activation of naive CD4+ T cells, only in studies using T cell blasts. CTLA-4 shares its ligands with CD28, and, importantly, has a 10-fold greater affinity for both CD80 and CD86 than its competitor CD28. Its role in modulating T cell activation has been demonstrated in several models including tumor rejection, allograft rejection, and autoimmune disease, whereby blockade of CTLA-4 leads to a profound increase in T cell proliferation and enhanced effector function. 32 Therefore it was no surprise to find that CTLA-4-deficient mice die of a fatal polyclonal expansion of T cells. 48 Despite extensive studies of CTLA-4 in terms of kinetics, localization, and activities in vivo and in vitro, the physiological role of this molecule requires further investigation. In this regard, there are two major hypotheses existing to compartmentalize the role of CTLA-4 in the fate of T cells during an immune response (as reviewed in Chambers  and Allison  31 and Chambers   32 ). The first suggests that, during an ongoing proliferative T cell response, there is a substantial expansion of antigen-specific T cells against a specific pathogen or tumor cell. Once the pathogen has been removed, a mechanism must be in place to attenuate these effector T cells as to prevent unnecessary tissue damage and potential triggering of autoimmunity. Therefore, the kinetics and persistence of CTLA-4 on preactivated and effector T cells, respectively, could provide a negative signal to terminate the T cell response. The second model, equally feasible, is that under conditions of encountering peptide-MHC on a nonprofessional APC or in the presence of limiting levels of CD80 and CD86, CTLA-4 engagement would predominate and T cell activation would be prevented or terminated (Figure 1) . Conversely, in the presence of high densities of CD80 and CD86 expression, such as found on professional APCs, including DCs and activated B cells, CD28-mediated costimulation would attain the desired threshold for T cell activation ( Figure 1) . Thus, the outcome of CD28-mediated costimulatory signals must directly compete with those delivered via CTLA-4.
As outlined above, during an immune response there are numerous signals delivered to the T cell from the APC including costimulatory and secreted molecules. Understanding exactly how T cells or DCs are able to integrate these diverse signals responsible for future activities is puzzling. An ambitious report by Gett and Hodgkin 49 describes a quantitative model to determine the 'calculus' used by the T cell to translate the signals induced via independent molecular interactions. The findings of the study convey the need to question our interpretation of in vitro findings with regard to costimulation and to challenge the two-signal theory. Many molecules described as being obligatory for costimulation are suggested to be only enhancing an ongoing effect of TCR engagement. 49 The Figure 1 The fate of a T cell is dependent on sufficient levels of costimulation. Naive T cells encountering a professional APC such as a mature DC with high surface expression of costimulatory molecules (CD80, CD86, and CD40) and high levels of antigenic peptide (Ag) will receive both signal 1 (TCR) and signal 2 (CD28) and become activated and undergo clonal expansion. Under conditions where the levels of costimulatory molecules are suboptimal such as on a resting B cell, signals delivered via the interaction of CTLA-4 will override those delivered by CD28 engagement and the T cell may not be activated or even become nonresponsive or anergic.
model described in this report may be useful to assess in vitro the relative role of candidate molecules involved in T cell activation or tolerance and could prove important in shaping the future of targets chosen for immunotherapeutic drug design.
RETROGRADE SIGNALING: THE ART OF COMMUNICATION
There is evidence that communication between DCs and naive T cells is more of a dialogue, as opposed to a T celldirected monologue, in which DCs also respond to signals given by interacting antigen-specific T cells. 33 Data suggest that recognition of the appropriate MHC-peptide complex causes CD4+ T helper cells to 'condition' DCs in a manner to allow them to perform other functions, such as to independently prime CD8+ CTLs. 7, 50 An example of this 'two-way' dialogue is the interaction of CD40, another member of the TNF receptor family, and its ligand, CD40-L. 7, 51 CD40 is expressed at low levels on immature DCs, and similar to CD80 and CD86, it is rapidly induced upon DC maturation. CD40L is expressed on the surface of T cells during early activation. 51 Studies of CD40 : CD40L interactions suggest two major functions of CD40 on DCs. 34 Firstly, retrograde signaling via CD40 is the most potent stimulus for the upregulation of both CD80 and CD86 expression on the DC surface. This increased expression culminates in increased engagement of CD80 and CD86 with CD28. CD40 : CD40L-induced increases in cell surface costimulatory molecule expression is also found in B cells. These protein interactions are essential for providing costimulation to the T cell. 52 Analogous to blockade of CD28, blocking CD86 with mAbs potently inhibits both antigen-specific and allogeneic T cell responses. 32, 34, 53 Secondly, soluble CD40L or CD40-Ig inhibits the DC stimulatory capacity for allogeneic T cells, indicating that CD40 : CD40L interactions provide vital costimulatory signals to the T cell. 32 Retrograde signaling effects may support a recent hypothesis that CD40-mediated conditioning of DCs by Th1 CD4+ T cells facilitates the ability of DCs to be independently capable of priming naive CTLs without the requirement of the CD4+ T helper cells and CD8+ CTLs to recognize the same antigen on the same APC. 7, 28 Logically, it would override the long-standing and conceptually difficult theory that all three cell types must find one another simultaneously and in the same immunological compartment. 54, 55 The functions of CD40-mediated conditioning are likely to extend to other cells that were previously thought to require direct T cell help, such as B lymphocytes. Therefore, the interactions between T cells and DCs allow optimal interactions with one another and provide an environment conducive to T cell signaling and activation for both CD4+ helper cells and CD8+ CTLs.
FORMATION OF THE IMMUNOLOGICAL SYNAPSE: KEEPING IT TOGETHER
The interaction of DCs with naive T cells is far more complex than simple juxta-positioning of cellular membranes. Several studies by numerous investigators have published impressive immunofluorescent images demonstrating the formation of highly structured foci known as supramolecular activation complexes (SMACs) at the interface of T cells and MHC Class II-peptide-bearing B cells. [56] [57] [58] These complexes are often referred to as the 'immunological synapse' based on their structural likeness to synapses found in the central nervous system. Formation of the SMAC (Figure 2 ) occurs via extensive cytoskeletal reorganization of many of the surface receptors and signaling elements involved in T cell activation and hence assumed to be vital in antigen-dependent T cell activation. 56, 57, 59 The 'mature' SMAC has a characteristic peripheral ring (pSMAC) composed of adhesion molecules, predominantly LFA-1 bound to ICAMs on the APC. 57 Within the pSMAC is a central zone (cSMAC) in which the T cell and APC plasma membranes were found to be in close proximity and the region in which the TCR-MHC-peptide and necessary costimulatory and signaling components are tightly clustered (Figure 2 ). The TCRs are concentrated two-to three-fold higher at the cSMAC than found in the remaining membrane of the cell. The SMAC complex is a highly dynamic structure, as illustrated by studies showing that in only a number of minutes a T cell engaged with a specific APC can detach and reorganize its cytoskeleton to form other or additional synapses with an APC presenting greater amounts of antigenic peptide. 60, 61 However, the majority of these studies were performed using either B cells or surrogate APC such as B cell hybridomas or lipid planar bilayers with glycosylphosphatidylinositol (GPI)-anchored molecules and T cell clones. The formation of the SMAC was assumed to be antigendependent, 56 as in the absence of antigen these structures did not exist. Correspondingly, the formation of the synapse could be prevented by the presence of altered or antagonistic peptides. 56, 57 With regard to DCs, the most recent study using DCs has raised novel questions regarding SMAC formation. Revy et al 24 showed that DCs can induce the formation of synapses or SMAC-like structures with polyclonal naive T cells (CD4+ helper T cells and CD8+ CTLs) in the absence of nominal antigen, or with only the presentation of self-peptide(s). As demonstrated with B cells, the T cells engaging with DCs underwent cytoskeletal re-organization with polarization of CD3, and CD4 molecules at the contact zone or cSMAC (Figure 2 ). The T cell microtubuleorganizing center (MTOC) was found at the T cell-DC synapse, whereas the DC MTOC was situated elsewhere and, in some cases, the T cell developed another SMAC complex at the opposite pole of the cell. 24 As described with B : T cell interactions, CD43 was excluded and CD45 included within the cSMAC of the contact zone betweens DCs and T cells. However, these studies did not show any clustering of LFA-1 or any other DC surface molecule at the contact zone and even questioned the presence of a 'true' SMAC in DC : T cell interactions. 24 To date, the existence or composition of the synapse occurring during a cognate DC : T cell interaction is lacking. Moreover, in assuming the formation of a SMAC complex between DCs and naive T cells exists, one has to reconcile the major differences between those studies on B cells and those on DCs. For example, B cells do not have constitutive co-stimulatory activity and, as with DCs or macrophages, they can be induced to express CD80 and CD86 with microbial agents. DCs are highly equipped to present a diverse range of antigens, while B cells specialize in presenting fragments to which their surface immunoglobulin binds. Therefore, the requirements to form a synapse and its duration are likely to differ between these two APC populations. Indeed, direct evidence of a long-lived synapse including a 'stop' signal, as derived from studies on B cells, is currently lacking for DCs. It is unclear how DCs are able to sustain a long-lived synapse formation as DCs, given that their membrane composition is highly dynamic and they undergo frequent morphological changes. 62 Moreover, the interaction of T cells with DCs has a strong migratory component and the durations of these engagements are short; the average time of contact is estimated to be 2-12 min. Supporting the serial triggering model, 62 naive T cells were previously shown by time-lapse video microscopy to interact sequentially with numerous DCs and calcium flux during the time of crawling across until shortly before detachment with each individual DC. 63 Therefore, synapse formation and consequent signaling events would have to occur very rapidly as compared to the long-lived synapse described for B cells. It may emerge that differences in molecular interactions that occur at the contact zone during the engagement of a DC, or B cell, with a T cell may provide a definitive reason as to why DCs are superior as APC. The basis for their heightened ability to prime naive T cells is often accountable to increased expression levels of MHC Class II (and peptide) and costimulatory molecules on the DC surface. Another possibility may be a superior ability to create synapses with interacting naive cells, and these may be facilitated specifically by expression of a particular surface molecule such as the ICAM-grabbing molecule such as DC-SIGN. 16 There are many important questions open with regard to not only the nature but also the role of SMAC between T cells and APC. Numerous investigators still regard the SMAC as being necessary for sustaining T cell signaling and hence T cell activation. Other reports have suggested that the cytoskeletal reorganization is necessary for T cell polarization of secreted cytokines. 64 Indeed, in the experimental findings by Lee et al, 65 CD4+ T cells recognize peptide-MHC on the B cells and begin signaling prior to synapse formation. It may also be the case that synapse formation is necessary to sustain the initial signaling. Alternatively, since SMAC formation precedes the endocytosis of TCRs, perhaps the role of the SMAC is to attenuate T cell responses as opposed to sustaining them, thereby acting in a negative feedback loop. Indeed, the data provided by Grakoui et al, 57 despite hypothesizing that the role of the synapse was in T cell activation, actually support Lee et al. 65 Grakoui et al 57 demonstrated that TCR molecule clustering within the central zone of the SMAC is greatest within the initial 5 min, and then many of the TCR molecules are subsequently lost from the mature synapse. During the first 30 s of cellular contact, they could show that the first step prior to synapse formation was TCR engagement of MHC-peptide situated in the peripheral region, and clustering of LFA-1 with ICAM molecules in the central region of the interacting membrane. 57 The synapse described by Monks et al 56 was demonstrated in experiments where the cells were fixed 30 min after T cell and APC coculture, and hence at this 'mature' stage the LFA-1 molecules have already migrated to the pSMAC and the TCR inwards to the central region. 56 
MHC-PEPTIDE PATCHES: MIRRORING THE SYNAPSE
Similar to the marked clustering of TCR molecules on the T cell interface, APCs also precluster their MHC-peptide complexes perhaps to assist in stabilizing the interactions with the SMAC present on the T cell surface. Recent data using MHC-peptide oligomers showed that a single Class IIpeptide complex is not sufficient to induce CD4+ T cell activation. 66 Studies using synthetic MHC-peptide complexes demonstrated that the minimum number of complexes were dimers. 66 Indeed, early crystallography studies were somewhat surprising in the finding that MHC Class II as well as TCR molecules were associated as dimers of dimers. [67] [68] [69] [70] Accordingly, DCs store substantial loads of MHC-peptide complexes within specialized vesicles (MIICs), which upon maturation are delivered to the plasma membrane and released. It has been suggested that these MHC molecules are likely to contain a number of identical peptides and be able to bring numerous TCR molecules and their associated co-receptors into close proximity with one another. Therefore, DCs could also be assumed to form their own individual supramolecular MHC-peptide activation complexes. While the data are lacking, one can envisage that there will be organization of costimulatory molecules, for example, DC-SIGN, CD80, CD86, CD40, and adhesion molecules on the DC surface, comparable to that found on the T lymphocyte.
SIZE EXCLUSION OR FREEZE-THAW
One of the most intriguing aspects of this molecular complex is the selectivity for the molecules allowed within the SMAC. In addition to ensuring that all the machinery is in place for promoting or sustaining T cell signaling, the formation of the SMAC is unique in its ability to exclude molecules deleterious to its function via steric hindrance. 71 In essence, larger proteins are displaced by numerous smaller molecules and remain in the peripheral SMAC of the mature synapse (Figure 2 ). This is known as the 'size exclusion' model. These exclusions include large proteins such as the glycoprotein CD43 and the protein phosphatase CD45, thus supposedly favoring maintenance of phosphorylation and sustained activation signaling events. CD43 exclusion has been demonstrated consistently by immunofluorescence staining on T cells interacting with B cells or DCs. 24, 56 Together, CD43 and CD45 constitute greater than 30% of the T cell membrane proteins. However, this model is problematic as CD45 is depleted from the cSMAC synapse formation but re-enters this region. Another molecule is CD4, which extends from the T cell membrane to interact with proximal membrane regions of MHC molecules present at the APC surface. Similar to CD45, CD4 is initially colocalized with the TCR and then excluded from the synapse. 72 A more appropriate model suggested by Delon et al is the 'freeze-thaw' model and fits with the dynamic properties of the synapse. 72 It has been demonstrated very elegantly that distribution and movement of CD43 is regulated by the phosphorylation status of moesin. Moesin is expressed in many cell types and functions to maintain surface molecule attachments to the actin cytoskeleton. 73 Dephosphorylation of moesin causes it to uncouple from the actin cytoskeleton and subsequently detach from bound CD43. Thus CD43 migrates from the central region of the SMAC and is then anchored in a region outside the central core by rephosphorylated moesin. 74 It is likely, although not described, that changes in the distribution of CD45 at the sight of APC contact are mediated by a similar mechanism or perhaps another cytoskeletal component. However, the absence of CD45 does not absolutely predispose to T cell activation as was indicated by the observation that CD45-deficient T cells cannot be activated. 75 It has been recently postulated that receptor clustering via formation of the SMAC alone is also not a prerequisite for T cell activation but rather that the direct exclusion of phosphatase activity is of greater importance. 71 CD45 is required to activate p56 lck by dephosphorylation; thus the only scenario in which p56 lck can phosphorylate another substrate is by segregating itself from CD45. Biochemical studies on T cells have shown the colocalization of molecules required for T cell activation (such as the TCR, CD28, and lck) to be in lipid rafts, which likely mediate the rapid movement of such moieties during cytoskeletal reorganization. 59 
LIPID RAFTS: FREEDOM AND CHOICE
In terms of SMAC formation, it is difficult to dissect the order of events that occur from the time of antigenrecognition to cytoskeletal reorganization and triggering of signaling cascades. It is conceivable that the SMAC formation is a direct result of lipid raft accumulation, microdomains rich in sphingolipid and cholesterol molecules and often described as traveling in a 'sea of phospholipids' on the cell surface. 76, 77 Alternatively, the shuttling of lipid rafts may be a direct consequence of TCR engagement with MHC-peptide. Like the SMAC, lipid rafts specifically segregate or sequester proteins, the mechanism of which remains elusive. On the T lymphocyte, the TCR had been associated with lipid rafts containing the src family kinases lck, lyn, and Fyn, to name a few, and these are required for the initial phosphorylation of the TCR. 78 CD45 is excluded from lipid rafts. In addition, MHC Class II molecules and CD40 have also been found on the lipid raft domains present on the surface of DCs and B cells. 79, 80 The role of these rafts seems likely to be in providing a platform for the colocalization of signaling and cytoskeletal components necessary for translating the interactions of extracellular domains of surface molecules with their corresponding ligands to those signaling proteins at the intracellular level. Raft members are continuously emerging, mainly by biochemical studies, and provide important insight as to which players are collectively necessary for individual immune cell activities. Reports to date have focused on those groups important in immune cell activation, but it is likely that lipid rafts will also be vital to other processes including induction of T cell tolerance and retrograde signaling with the APC during antigen-specific recognition.
EXPLOITING DC IMMUNOBIOLOGY FOR CELLULAR-OR DNA-BASED VACCINATION STRATEGIES
The optimal capabilities of DCs to uptake, process, and present antigen is clear; thus many investigators strive to find methods to manipulate or exploit DCs in immunotherapy approaches. In recent years, a novel vaccination strategy known as DNA vaccination has been shown to be able to trigger both the humoral and cellular arms of the immune response. 81 The reasons for its efficacy are beginning to unfold, especially the central role of DCs. DNA vaccination is in essence a relatively simple treatment whereby the gene encoding a particular antigen of interest is cloned into a chosen bacterial plasmid under the control of either a eukaroytic or viral promotor. The DNA is administered by intramuscular or intradermal injection and resident cells including fibroblast, myoblasts, and keratinocytes become transfected. However, these cells do not migrate and naive antigen-specific T cells do not have a tendency to circulate through tissues, so the mechanism of action of DNA vaccination was confusing to many investigators. It is now appreciated that resident DCs are able to capture Ag(s) or antigenic peptides directly or indirectly from transfected cells undergoing apoptosis in the area of immunization. Furthermore, unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides present on some DNA vaccines act as a potent adjuvant for DC activation. 82 This became evident with the discovery of a CpG receptor present on DCs known as Toll-like receptor-9 (TLR-9), another member of the growing Toll-like receptor family. These receptors are fundamental in the activities of DCs, as they mediate the connection between the innate and acquired immune responses. Indeed TLR9 À/À mice are unresponsive to CpGcontaining DNA. 82 As mentioned, there is increasing evidence of the role of DCs in DNA vaccination strategies. 81 One of the most elegant experiments to demonstrate this was shown in chimeric mice in which H-2 bxd recipient mice were reconstituted with either MHC haplotype of H-2 b or H-2 d from bone-marrow donors. 83 The same mice received a DNA vaccination using DNA encoding the influenza nucleoprotein that had epitopes restricted to the haplotypes of both donors. The result was a strong CTL response to the haplotype of the donor marrow cells and not that of the recipient, suggesting the role of bone-marrow-derived APC. More recently, green fluorescent protein (GFP), a reporter gene used in several DNA vectors, was found to be expressed in the DCs in draining lymph nodes following intradermal DNA vaccination. 84 Notably, DCs are known for their ability to cross-prime by uptake of exogenous antigen from transfected cells and to cross present antigenic peptide(s) to naive T cells, not only via MHC Class II but also on MHC Class I molecules. Hence DCs are able to induce potent CTL responses. 81 In addition to the in vivo role of DCs in DNA vaccination, several approaches have been used to 'educate' the DCs with target antigens for use in clinical trials. A number of groups are pursuing DC-based immunotherapy trials for cancer. In the first reported trial, autologous DCs were pulsed ex vivo with tumor-specific antigen from patients with malignant Bcell lymphoma. [85] [86] [87] The surface immunoglobulin receptors from these neoplastic cells were purified and used to pulse autologous DCs in vitro and delivered by intravenous infusion to the patients. 88 The majority of these patients developed an anti-idiotype response specific to the tumor immunoglobulin and two of the patients underwent complete tumor regression. Two DC-based vaccine trials have also been described for melanoma in which DCs were pulsed with a panel of melanoma-derived peptides. The majority of these patients showed a clinical response and a small number showed complete remission. 89, 90 These studies indicate the ability to manipulate DCs for a particular application such as the induction of a desired immune response against a tumor. It may also be possible to treat DCs ex vivo with antigen and under conditions to impair DC function. One approach would be to develop blocking antibodies to those molecules involved in DC-T cell interactions to restore self-tolerance in the case of autoimmune diseases such as diabetes or rheumatoid arthritis. In the light of DNA vaccination, one may be able to generate vectors that also deliver a particular cytokine or immunoregulatory product to modulate the activities of resident DCs that capture and deliver antigen to naive T cells in the draining lymph nodes. One candidate of a DC-specific target is DC-SIGN, which is found only in T cell areas of secondary lymph nodes and, as mentioned, may be vital in the adhesive interactions with T cells. 17, 18 Despite the advances in our understanding of T cell : APC interactions, the exact mechanisms responsible for these extensive cytoskeletal and molecular rearrangements are still to be unraveled and more experimental evidence is required. However, from a pharmacogenomic angle, the possibilities for intervention are endless given the complexity of these interactions. Future trials performing ex vivo treatment of DCs or in vivo targeting of DCs open an exciting new area for the development of immunomodulatory therapies.
